Funding boost will take Lead Program Inhibitor forward : com

Pre-clinical biotech BiPER Therapeutics, (Strasbourg) a developer of first-in-class drug candidates targeting BiP protein to treat gastrointestinal cancers has raised a total of €1. Click to read more...

Related Keywords

France , French , Wiclub Sant , Guillaume Vetter Genoud , Cyril Ronco , Stephane Rocchi , Rachid Benhida , Mehdi Chelbi , Zaki Sellam , , Grand Est , Clinical Trial Application , Investigational New Drug , Endoplasmic Reticulum , Landmark Bioventure , Morgan Rapinat , Cancer , Viper , Funding , Linical , Herapeutics , Drug , Gastrointestinal , Need , Company , Purok ,